[38] Park JW, Kim JH, Kim SK, et al. A prospective
evaluation of 18F-FDG and 11C-acetate PET/CT for detection of primary and
metastatic hepatocellular carcinoma[J]. J Nucl Med, 2008, 49(12): 1912-21. [39] Boellaard R, O'doherty MJ, Weber WA, et al. FDG
PET and PET/CT: EANM procedure guidelines for tumour PET imaging: version
1.0[J]. Eur J Nucl Med Mol Imaging, 2010, 37(1): 181-200. [40] Chalian H, Tore HG, Horowitz JM, et al.
Radiologic assessment of response to therapy: comparison of RECIST Versions 1.1
and 1.0[J]. Radiographics, 2011, 31(7):2093-105. [41] Wahl RL, Jacene H, Kasamon Y, et al. From RECIST
to PERCIST: Evolving Considerations for PET response criteria in solid
tumors[J]. J Nucl Med, 2009, 50 Suppl 1(Suppl 1): 122S-50S. [42] Ferda J, Ferdova E, Baxa J, et al. The role of
18F-FDG accumulation and arterial enhancement as biomarkers in the assessment
of typing, grading and staging of hepatocellular carcinoma using 18F-FDG-PET/CT
with integrated dual-phase CT angiography[J]. Anticancer Res, 2015, 35(4):
2241-6. [43] Hyun SH, Eo JS, Lee JW, et al. Prognostic value
of 18F-fluorodeoxyglucose positron emission tomography/computed tomography in
patients with Barcelona Clinic Liver Cancer stages 0 and A hepatocellular
carcinomas: a multicenter retrospective cohort study[J]. Eur J Nucl Med Mol
Imaging, 2016. [44] Lee JW, Oh JK, Chung YA, et al. Prognostic
Significance of ¹⁸F-FDG Uptake in Hepatocellular Carcinoma Treated with
Transarterial Chemoembolization or Concurrent Chemoradiotherapy: A Multicenter
Retrospective Cohort Study[J]. J Nucl Med, 2016, 57(4): 509-16. [45] Na SJ, Oh JK, Hyun SH, et al. (18)F-FDG PET/CT
Can Predict Survival of Advanced Hepatocellular Carcinoma Patients: A
Multicenter Retrospective Cohort Study[J]. J Nucl Med, 2017, 58(5): 730-6. [46] Bertagna F, Bertoli M, Bosio G, et al. Diagnostic
role of radiolabelled choline PET or PET/CT in hepatocellular carcinoma: a
systematic review and meta-analysis[J]. Hepatol Int, 2014, 8(4): 493-500. [47] Cheung TT, Ho CL, Lo CM, et al. 11C-acetate and
18F-FDG PET/CT for clinical staging and selection of patients with
hepatocellular carcinoma for liver transplantation on the basis of Milan
criteria: surgeon's perspective[J]. J Nucl Med, 2013, 54(2): 192-200. [48] Zhang Y, Shi H, Cheng D, et al. Added value of
SPECT/spiral CT versus SPECT in diagnosing solitary spinal lesions in patients
with extraskeletal malignancies[J]. Nucl Med Commun, 2013, 34(5): 451-8. [49] Hectors SJ, Wagner M, Besa C, et al.
Multiparametric FDG-PET/MRI of Hepatocellular Carcinoma: Initial Experience[J].
Contrast Media Mol Imaging, 2018, 2018: 5638283. [50] Zhou J, Yu L, Gao X, et al. Plasma microRNA panel
to diagnose hepatitis B virus-related hepatocellular carcinoma[J]. J Clin
Oncol, 2011, 29(36): 4781-8. [51] Best J, Bechmann LP, Sowa JP, et al. GALAD Score
Detects Early Hepatocellular Carcinoma in an International Cohort of Patients
With Nonalcoholic Steatohepatitis[J]. Clin Gastroenterol Hepatol, 2020, 18(3):
728-35.e4. [52] Forner A, Vilana R, Ayuso C, et al. Diagnosis of
hepatic nodules 20 mm or smaller in cirrhosis: Prospective validation of the
noninvasive diagnostic criteria for hepatocellular carcinoma[J]. Hepatology,
2008, 47(1): 97-104. [53] Roberts LR, Sirlin CB, Zaiem F, et al. Imaging
for the diagnosis of hepatocellular carcinoma: A systematic review and
meta-analysis[J]. Hepatology, 2018, 67(1):401-21. [54] EASL Clinical Practice Guidelines: Management of hepatocellular
carcinoma[J]. J Hepatol, 2018, 69(1): 182-236. [55] Huang YH, Zhang CZ, Huang QS, et al.
Clinicopathologic features, tumor immune microenvironment and genomic landscape
of Epstein-Barr virus-associated intrahepatic cholangiocarcinoma[J]. J Hepatol,
2021, 74(4): 838-49. [56] Yu WL, Yu G, Dong H, et al. Proteomics analysis
identified TPI1 as a novel biomarker for predicting recurrence of intrahepatic
cholangiocarcinoma[J]. J Gastroenterol, 2020, 55(12): 1171-82. [57] Paradis V, Fukayama M, Park Y, et al. Tumours of
liver and intrahepatic bile ducts[M]. 5 ed. Lyon, France: IARC Press, 2019. [58] Cong WM. Surgical pathology of hepatobiliary
tumors[M]. 1 ed. Singapore: Springer, 2017. [59] Cong WM, Bu H, Chen J, et al. Practice guidelines
for the pathological diagnosis of primary liver cancer: 2015 update[J]. World J
Gastroenterol, 2016, 22(42):9279-87. [60] Chen L, Chen S, Zhou Q, et al. Microvascular
Invasion Status and Its Survival Impact in Hepatocellular Carcinoma Depend on
Tissue Sampling Protocol[J]. Ann Surg Oncol, 2021, 28(11): 6747-57. [61] Nara S, Shimada K, Sakamoto Y, et al. Prognostic
impact of marginal resection for patients with solitary hepatocellular
carcinoma: evidence from 570 hepatectomies[J]. Surgery, 2012, 151(4): 526-36. [62] Cong W: [Hepacocellular Carcinoma], Cong W,
editor, Surgical pathology of liver and gallbaldder tumors, Beijing: People's
Medical Publishing House, 2015:276-320. [63] Scheuer PJ. Classification of chronic viral
hepatitis: a need for reassessment[J]. J Hepatol, 1991, 13(3): 372-4. [64] Regimens for prevention and treatment of viral
hepatitis[J]. Chinese Journal of Infectious Diseases, 2001, 19(1): 56-62. [65] Guidelines
for the Prevention, Care and Treatment of Persons with Chronic Hepatitis B Infection,
Geneva, 2015. [66] Rodriguez-Peralvarez M, Luong TV, Andreana L, et
al. A systematic review of microvascular invasion in hepatocellular carcinoma:
diagnostic and prognostic variability[J]. Ann Surg Oncol, 2013, 20(1): 325-39. [67] Chinese Societies of Liver Cancer Ca-CA, Liver
Cancer Study Group CSOH, Chinese Medical Association, Chinese Societies of
Pathology Ca-CA, et al. Evidence-based practice guidelines for the standardized
pathological diagnosis of primary liver cancer(2015 edition)[J]. Chinese
Journal of Hepatobiliary Surgery, 2015, 21(3): 145-51. [68] Sheng X, Ji Y, Ren GP, et al. A standardized
pathological proposal for evaluating microvascular invasion of hepatocellular
carcinoma: a multicenter study by LCPGC[J]. Hepatol Int, 2020, 14(6): 1034-47. [69] Isik B, Gonultas F, Sahin T, et al. Microvascular
Venous Invasion in Hepatocellular Carcinoma: Why Do Recurrences Occur?[J]. J
Gastrointest Cancer, 2020, 51(4): 1133-6. [70] Zhang X, Li J, Shen F, et al. Significance of
presence of microvascular invasion in specimens obtained after surgical
treatment of hepatocellular carcinoma[J]. J Gastroenterol Hepatol, 2018, 33(2):
347-54. [71] Travis WD, Dacic S, Wistuba I, et al. IASLC
Multidisciplinary Recommendations for Pathologic Assessment of Lung Cancer
Resection Specimens After Neoadjuvant Therapy[J]. J Thorac Oncol, 2020, 15(5):
709-40. [72] Allard MA, Sebagh M, Ruiz A, et al. Does
pathological response after transarterial chemoembolization for hepatocellular
carcinoma in cirrhotic patients with cirrhosis predict outcome after liver
resection or transplantation?[J]. J Hepatol, 2015, 63(1): 83-92 [73] Stein JE, Lipson EJ, Cottrell TR, et al.
Pan-Tumor Pathologic Scoring of Response to PD-(L)1 Blockade[J]. Clin Cancer
Res, 2020, 26(3): 545-51. [74] Imamura H, Seyama Y, Kokudo N, et al. One
thousand fifty-six hepatectomies without mortality in 8 years[J]. Arch Surg,
2003, 138(11): 1198-206; discussion 206. [75] Kubota K, Makuuchi M, Kusaka K, et al.
Measurement of liver volume and hepatic functional reserve as a guide to
decision-making in resectional surgery for hepatic tumors[J]. Hepatology, 1997,
26(5): 1176-81.
|
